Pacira BioSciences (NASDAQ:PCRX) Raised to Buy at Wall Street Zen

Pacira BioSciences (NASDAQ:PCRX) was upgraded by equities research analysts at Wall Street Zen from a “hold” rating to a “buy” rating in a research report issued on Friday.

PCRX has been the topic of a number of other reports. HC Wainwright boosted their price objective on Pacira BioSciences from $48.00 to $65.00 and gave the company a “buy” rating in a research report on Tuesday, April 8th. Needham & Company LLC lowered their price objective on Pacira BioSciences from $32.00 to $30.00 and set a “buy” rating on the stock in a research report on Friday, May 9th. Finally, Barclays boosted their price target on Pacira BioSciences from $17.00 to $24.00 and gave the company an “overweight” rating in a research note on Friday, February 28th. One equities research analyst has rated the stock with a sell rating, four have issued a hold rating and five have given a buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus target price of $26.44.

Pacira BioSciences Stock Down 2.9%

PCRX opened at $25.97 on Friday. The company has a debt-to-equity ratio of 0.51, a quick ratio of 1.89 and a current ratio of 2.25. The business has a 50 day moving average price of $25.53 and a 200 day moving average price of $23.37. The firm has a market cap of $1.20 billion, a P/E ratio of -12.79 and a beta of 0.52. Pacira BioSciences has a twelve month low of $11.16 and a twelve month high of $29.95.

Insider Activity at Pacira BioSciences

In other news, SVP Lauren Riker sold 5,578 shares of the stock in a transaction on Wednesday, June 4th. The stock was sold at an average price of $26.21, for a total transaction of $146,199.38. Following the sale, the senior vice president now owns 59,564 shares in the company, valued at approximately $1,561,172.44. This represents a 8.56% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. 6.40% of the stock is owned by insiders.

Institutional Trading of Pacira BioSciences

Several large investors have recently made changes to their positions in the business. Sterling Capital Management LLC lifted its stake in shares of Pacira BioSciences by 779.4% during the fourth quarter. Sterling Capital Management LLC now owns 1,363 shares of the company’s stock valued at $26,000 after acquiring an additional 1,208 shares during the period. Ancora Advisors LLC bought a new position in shares of Pacira BioSciences during the 4th quarter valued at about $26,000. Caitlin John LLC lifted its holdings in shares of Pacira BioSciences by 1,850.0% during the 4th quarter. Caitlin John LLC now owns 1,872 shares of the company’s stock valued at $35,000 after purchasing an additional 1,776 shares in the last quarter. Caitong International Asset Management Co. Ltd acquired a new stake in Pacira BioSciences in the 1st quarter valued at approximately $51,000. Finally, US Bancorp DE increased its position in shares of Pacira BioSciences by 31.0% during the 1st quarter. US Bancorp DE now owns 2,270 shares of the company’s stock worth $56,000 after purchasing an additional 537 shares during the last quarter. Institutional investors own 99.73% of the company’s stock.

About Pacira BioSciences

Pacira Biosciences, Inc is a holding company, which engages in the provision of non-opioid pain management and regenerative health solutions to improve patients’ journeys along the neural pain pathway. Its products include EXPAREL, iovera, and DepoFoam. The company was founded in December 2006 and is headquartered in Tampa, FL.